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Abstract: Left sided endocarditis (LSE) can include the entirety or portion of mitral and/or aortic valve 
and the structures in their anatomical contiguity and represent a significant portion of emergency surgical 
activity. Literature and guidelines on the management of LSE relies mainly on observational studies given 
the difficulty in designing randomized trials in emergency settings. Heart teams (HT) are often called in to 
difficult decisions on the most appropriate strategy to adopted in case of LSE. Decision-making should take 
into account the localization and the extension of the infection, patient preoperative status and comorbidities, 
presence of a previous valve prosthesis and best timing for surgery. Despite evidence suggests that early 
surgery may improve survival in patients with complicated infective endocarditis (IE), an increased risk of 
recurrence and postoperative valvular dysfunctions has been reported. The most important factors associated 
with long-term outcomes are preoperative multiorgan failure, prosthetic mechanical valve IE, vegetation 
size ≥15 mm, and timing of surgical treatment. Importantly, up to one third of potential candidates do not 
undergo surgery and these patients experience extremely high mortality rates. Another important point 
regards the choice of the optimal valve substitute to be used according to the different clinical situation. The 
lack of RCT in this field and the difficulty to design this type of studies in the case of non-elective conditions 
further complicates the possibility to achieve a univocal consensus on the best strategy to be adopted in each 
form of LSE and further validation studies are needed. On the basis of the current evidences a decisional 
algorithm is proposed summarizing all the crucial aspects in the management of LSE.
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Introduction
Left sided endocarditis (LSE) is an infection of the entirety 
or portion of mitral and/or aortic valve and the structures 
in their anatomical contiguity. It may be determined by 
various pathogens, but bacterial origin is the most common. 
In developed countries, LSE are one of the most common 
causes of acute valves failure. In some reports, the estimated 
annual prevalence of infective endocarditis (IE) was 3 to 9 
cases per 100,000 persons (1,2) and LSE affects native valves 
in 64% to 76.2% of the cases (3-5) and prosthetic valves in 
89.9% (PVE) (6,7).
In patients with LSE, age, evolutive cardiogenic shock, 
PVE, left ventricular ejection fraction (LVEF) <40%, and 
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recurrent infections are considered significant predictors 
of mortality (6-9). However, current evidence regarding 
the treatment and management strategy for LSE are not 
univocal and are often based on empirical practice.
This report aims at reviewing the current evidences on 
LSE and provides a basis for the management of this disease 
focusing on aspects of the heart team (HT) approach, on 
the selection of the most appropriate surgical strategy and 
on the importance of physician-patient discussion about the 
risks, benefits, and expectations after the surgery. 
We present the following article in accordance with the 
Narrative Review reporting checklist (available at http://
dx.doi.org/10.21037/atm-20-4439).
Methods
In December 2019, a search of the PubMed database using 
the terms “endocarditis”, “left side endocarditis”, “heart 
valve prosthesis”, “allograft”, “autograft”, “cardiac valve 
surgery”, “aortic valve replacement” was coordinated. 
Qualified abstracts were reviewed and the related articles 
were investigated. References for all selected studies were 
cross checked. Data from randomized controlled trials 
(RCT), unmatched observational series, observational 
series corresponding to propensity, meta-analysis, registries 
and expert opinion were included. It should be noted that 
weight of evidence regarding the different valve substitutes 
was not comparable among groups given the significantly 
larger number of observations for patients with xenograft 
(N=4,111), homografts (N=2,454) in comparison to 
mechanical prosthesis (N=655) Ross operation and valve 
repairs. Despite the majority of the observational studies 
are propensity matched, the lack of RCT and a number 




In the 21st century the central role of the multidisciplinary 
team emerged in the treatment of endocarditis and this is 
crucial for LSE management. Early diagnosis of the either 
native valve endocarditis (NVE) and PVE can favor both 
the optimization surgical timing and avoidance of potential 
complications. 
Lack of multidisciplinary integration could lead to delay 
in diagnosis, late referral for surgery of patients in more 
critical conditions after failure of medical treatment. 
In an Italian study, a formalized multidisciplinary team 
approach including (I) initial evaluation within the first 
12 hours, (II) indication for early surgery within 48 hours 
and (III) a re-evaluation of the patient’s clinical condition 
every week, led to a reduction in hospital mortality from 
28% to 13% (P=0.02) and in 3-year mortality from 34% vs. 
16% (P=0.0007), regardless age and comorbidities (38). The 
importance of tertiary centers with advanced surgical and 
management competencies is even more evident in complex 
LSE, and referral to these units can be advantageous not 
only in terms of clinical outcomes but also in terms of cost-
effectiveness for the national health systems. However, 
potential criticisms to this organizational model might 
regard the depletion of trained physicians in peripheral 
hospitals and the potential delays in transferring patients.
The treatment of IE in the current era requires a 
reconfiguration in the organizational standard towards a 
centralized system of care or, alternatively, the creation of 
a hub-and-speak model that is based on the activity of a 
multidisciplinary center reviewing clinical cases. This model 
would allow rapid and qualified initial management of IE 
and should be established on the basis of clinical evidence. 
There is no reason to doubt that the implementation of 
a centralized care can improve decision making, surgery 
timing, and short- and long-term results. Furthermore, the 
efficacy and validity of a centralized model could be readily 
tested in a study evaluating the difference between the 
before and after its creation (Figure 1).
Risk assessment
The risk assessment models for LSE aimed to assist the 
decision-making process of multidisciplinary team has a 
pivotal role during the discussion in HT (Figure 1, Table 3).
Gaca et al. (39) elaborated a surgical risk score for the IE 
based on the Society of Thoracic Surgeon’s database. The 
authors identified 13 risk factors for mortality, including 
emergency status, cardiogenic shock, hemodialysis, and 
“active endocarditis”.
Another single-center pilot study (40) included 440 
patients who had the surgery for NVE and reported six 
predictors for early postoperative mortality. Variables were 
entered in a mathematical model with good predictivity 
[area under receiver operating characteristic curve (AUC-
ROC) of 0.88]. The authors identified six predictors along 
with their assigned scores including age (5–13 points), 
renal failure (5), NYHA class IV (9), critical preoperative 
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210 118 162 Ao-H [210]; χ 
Ao/Mitr-H [11]
Similar survival at 15 years Ao-H (61.3%) vs. stented xenograft 
(62.1%) and vs. mechanical prosthesis (60.6%); 15 years 
freedom from reoperation SVD 89.4%. Freedom from IE 98.1% 
at 20 years. MACCEs freedom from event at 15 years 50.6%
Schaefer 2018, 
PLoS One (11)
#154 35 48.7 SFS [77] (IE 19); 
XP [77] (IE 16)
30-day mortality (SFS 3/77; 3.9% vs. CP 4/77; 5.2%; P=0.699). 
All-cause mortality (SFS 20.8% vs. CP 14.3%; P=0.397); SVD 
(5.2% SFS vs. 0% CP; P=0.04); Reoperation due to SVD or 
prosthetic valve endocarditis (PVE) (9.1% SFS vs. 1.3% CP; 
P=0.04). Inferior survival after NVE in re-do surgery in SFS 





190 190 144 Ross Operation 30 days mortality for the total study population of 2.1%. 
Survival 93.8% [95% confidence interval (CI): 90.2–97.7) at  
10 years and 86.1% (95% CI: 78.8–94.0) at 20 years. Freedom 
from reoperation on the auto- and homograft 94.1% (95% CI: 
83.6–100.0) at 5 years, 87.4% (95% CI: 72.4–100.0) at  
10 years, and 71.5% (51.1–100.0) at 15 years. Lower incidence 
of reoperation for autograft endocarditis 0.4%
Kim 2016, 
JTCVS (13)
304# 304 29.4 Ao-H [86]; MP 
[79]; XP [139]
Similar survival between valve substitute. Odds ratio 1.61; 95% 
confidence interval (CI), 0.73–3.40, P=0.23 (HR 1.10; 95% CI, 
0.62–1.94, P=0.75). Reinfection 7.7%. No difference in freedom 
from reinfection rates (P=0.65). CAH did not significantly affect 
reinfection (HR 1.04; 95% CI, 0.49–2.18, P=0.93)
Kim 2016, 
JTCVS (14)
436# IVDU 78;  
Non-IVDU 
358
29.4 Ao-H [86]; MP 
[99]; XP [206]
Similar survival between group (IVDU vs. Non IDVU). (HR, 0.78; 
95% CI, 0.44–1.37). No difference between valve substitute. 
Lower operative mortality in IVDUs (odds ratio, 0.25; 95% 
CI, 0.06–0.71). Better valve-related complications in IVDUs 
(HR, 3.82; 95% CI, 1.95–7.49; P<0.001) for higher rates of 
reinfection (HR, 6.20; 95% CI, 2.56–15.00; P<0.001)
Perrotta 2016, 
Ann Thorac  
Surg (15)
84 84 65 Ao-H [56]; MP 
[20]; XP [12]
10 years similar survival. CAH 58% vs. conventional prosthesis 
75% (P=0.17). Higher incidence of reoperation for infection 
relapse in mechanical or xenograft valve prosthesis (12.9%) 
than CHA (0%) (P=0.006). Lower incidence of reoperation for 
SVD in CAH at 10 years (5.3%)
Arabkhani 2016, 
JTCVS (16)
353 115 137 Ao-H [115] 20 years survival 40.0% at (95% CI, 32–50%). 20 years 
predicted competing-risks analysis 31% death without 
reoperation, 39% reoperation, and 30% alive without 
reoperation. Low incidence of infection relapse (3.96%) and 
reoperation (2.26%)
Flameng 2015, 
Ann Thorac  
Surg (17)
69 69 96 Ao-H [69] 10 years survival 73%. 10 years freedom of reoperation 74%. 
Lower incidence of infection relapse and reoperation for IE 




2,559 111 79 XP [111] (CP 
bioprosthesis)
15- and 20-year survival 31.1% and 14.4% (95% CI). IE early
Table 1 (continued)
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Ann Thorac  
Surg (19)
12,569 450 68 XP [450] (CP 
bioprosthesis)
76% probability of death before explant for SVD and 
endocarditis at 20 years. Few probabilities of explantation for 
SVD (5.4%) and endocarditis (1.4%) at 20 years
Chiang 2014, 
JAMA (20)
#2,002 16 128 MP [9]; XP [7] No difference in 30-day mortality XP (3%) vs. MP (3%) (P=0.49); 
No difference survival (P=0.74); 15-year survival XP (60.6%; 
95% CI, 56.3–64.9%) vs. MP (62.1%; 95% CI, 58.2–66.0%). 
HR 0.97 (95% CI, 0.83–1.14). 15 years reoperation XP (12.1%) 
vs. MP (6.9%) (95% CI, 8.8–15.4% vs. 95% CI, 4.2–9.6%. HR: 
0.52; 95% CI, 0.36–0.75)
Hussain 2014, 
JTCVS (21)
#775 537 84 Ao-H [357]; MP 
[25]; XP [139]
30 days mortality 7% for aortic valve and 14% for aortic and 




840 101 420 Ao-H [101] 35 years survival 66%. 35 years reoperation rate for SVD 
33.9%. 2 pts with CAH for more than 30 years. Lower 
incidence of infection relapse and reoperation for IE. Early 
reinfection 0.2%. Late relapse of IE 5.5%
Sénage 2014, 
Circulation (23)
617 44 XP [617] 
Mitroflow 
(models 12A/LX)
5 years survival 69.6% (95% CI, 65.7–73.9). Early SVD. 1-, 2-, 
and 5-year 0.2% (95% CI, 0.0–0.6), 0.8% (95% CI, 0.0–1.6), 
and 8.4% (95% CI, 5.3–11.3). 5-year SVD-free survival 91.6% 
(95% CI, 88.7–94.7). 13 patients accelerated SVD
Glaser 2014, Ann 
Thorac Surg (24)
1,219 8 50 XP (CP 864); XP 
(Mosaic 365)
No difference 8 years survival CP (63%) vs. Mosaic (57%) 
(P=0.971). (HR, 0.85; 95% CI, 0.65–1.11). No difference in 
reoperation (P=0.745). Lower incidence of IE recurrence
Grubitzsch 2014, 
JTCVS (6)
149 96 48 MP [11]; XP [80]; 
Ross  
Procedure [5]
Early death 31.5%. Late death 7.38%; overall and event-free 
survivals at 10 years were 75% +/- 3.8% and 64%, 4.0%; 
Freedom from recurrent infection and reoperation at 10 years 
were 81% +/- 3.6% and 91% +/- 2.6%
Kowert 2012, Eur 
J Cardiothorac 
Surg (25)
363 363 100 Ao-H [363] Early death 8.9%. Survival 1 year (86%) and 5 years (77.4%). 
Mean time between homograft implantation and redo operation 
8.4±3.6 years. Early and late recurrent endocarditis 9%  
(prior IE)
Manne 2012, 
Ann Thorac  
Surg (5)
428 282 12 Ao-H [173]; MP 
[24]; XP [84]; 
Ross operation 
[1]; Ao-R [12]
Higher 30-day mortality PVE vs. NVE (13% vs. 5.6%; 
P<0.01). No difference in survival NVE vs. PVE (35% vs. 
29%; P=0.19). Higher 30 days mortality and 1 year mortality 
for Staphylococcus aureus infection (15% vs. 8.4%; P<0.05) 
and (28% vs. 18%; P=0.02). Few reoperation for persistent 
infection or relapse (2.4%)
Mayer 2012, Eur 
J Cardiothorac 
Surg (26)
100 100 31 MP [10]; XP [51]; 
Ross operation 
[6]; Ao-R [33]
Similar 30-day mortality Ao-R 9% vs. Ao-Rpl 18% (P=0.37). 
Better survival Ao-R (88%) vs. Ao-Rpl (65%) (P=0.047). Higher 
rate of reoperation Ao-R (35%) vs. Ao-Rpl (10%) (P=0.021)
Bekkers 
2011, Eur J 
Cardiothorac 
Surg (27)
262 96 102 Ao-H [96] 30-day mortality 5.7%. Survival 77.0% (95% CI, 71–83%) at  
10 years, and 65.1% (95% CI, 57–74%) at 14 years. Survival after 
re-operation 87.1% at 1 year and 79.3% at 9 years. Freedom 
from allograft re-operation 82.9% at 10 years and 55.7%  
(SE 5.7%) at 14 years. SVD 18.5% and infection relapse 0.7%
Table 1 (continued)
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1,136 1,136 62 Ao-H [221] 10 years survival 47.3%±5.6%. Lower incidence (5.4%) of 
infection relapse and reoperation for IE. Lower incidence of 
reoperation for SVD 8.6%
El-Hamamsy 
2010, JACC (29)




Freestyle less progressive aortic valve dysfunction and a lower 
need for reoperation (100%±0% vs. 90%±5%; P=0.02). 30-day 
mortality 4.8%. No difference in survival freestyle vs. homograft 
(80 +/-5% vs. 77 +/- 6%; P=0.9)
Nguyen 
2010, Eur J 
Cardiothorac 
Surg (30)
167 167 60 Ao-H [77]; MP 
[109]; XP [31]
30-day mortality XP (19.4%), Ao-H (7.4%), MP (10.1%) 
(P=0.27). XP lower overall 5-year survival </=65 years [adjusted 
HR 4.14 (1.27–13.45), P=0.018] but not >65 years [adjusted 
HR: 1.45 (0.35–5.97), P=0.60]. No difference between Ao-H 
and MP [HR 0.46; 95% CI, (0.15–1.42), P=0.18]
Klieverik 2009, 
Ann Thorac  
Surg (31)
138 138 96 Ao-H [106]; MP 
[32]
Higher 30-day mortality for CAH (P=0.25). No difference in 
survival at 15 years (CAH 59%±6% and MP 66%±9% (P=0.68) 
and freedom from recurrent infection (P=0.29). Higher rates of 
reoperation for CAH (P=0.02)
David 2007, 
JTCVS (3)
383 383 73 Ao-H [18]; MP 
[214]; XP [133]
15 years survival 44%. Relapse of IE independent predictors 
of death (HR 2.2, 95% CI, 1.2–3.9). 15 years freedom from 
recurrent IE 86% for all patients without difference between 




816 816 60 Ao-H [182] 10 years survival 91%. Lower incidence of early (2.7%) and 
late (3.6%) infection relapse and reoperation for IE (P=0.0001). 
10–13 years freedom from reoperation for SVD 85%
Sabik 2002, Ann 
Thorac Surg (32)
103 103 51 Ao-H [103] 30-day mortality 3.9%. Survival at 10 years 56%. Few recurrent 
PVE at >/=2 years (peaked at 9 months)
Moon 2001, Ann 
Thorac Surg (31)
306# 306 183 Ao-H [20]; MP 
[65]; XP [221]
20 years survival 46% mechanical, 41%, stented xenograft, 
58% CAH; P>0.27. Lower risk of infection relapse without 
group difference. 5 years 2.1% mechanical prosthesis, 2.3% 
stented xenograft, and 3.6% CAH; P>0.88. After 5 years 0.5% 
mechanical prosthesis, 1.1% stented xenograft and 3.1% 
CAH; P>0.25. 10- and 15-year freedom from reoperation for 
mechanical prosthesis 74.6%; 10- and 15-year freedom from 
reoperation for xenograft prosthesis 56.6%, 22.6% P>0.64
Of total N=436 Valve repair was performed in N=45. #, propensity score; χ Ao/Mitr-H, cryopreserved mitro-aortic homograft replacement; 
IVDU, intravenous drug user.
status (39), failure to achieve preoperative blood culture 
negativity (5) and perivalvular involvement (5). They have 
outlined four risk classes ranging from “very low risk” (≤5 
points, expected average mortality of 1%), and “very high 
risk” (≥20 points, mortality of 43%). 
Martínez-Sellés et al. (41) included 26 observational 
reports with over 1,000 patients treated for LSE (NVE 
=315 and PVE =122). They reported a significant reduction 
in in-hospital mortality in patients who underwent early 
surgery compared to those were managed with medical 
therapy (24.3% vs. 34%; P=0.02). A risk score called 
PALSUS was developed which aimed to evaluate hospital 
mortality using seven prognostic variables with a similar 
predictive value. Variables included were: prosthetic valve, 
age ≥70, significant intracardiac destruction, Staphylococcus 
spp, urgent surgery, sex [female], EuroSCORE ≥10 (42). 
Nappi et al. Decision-making in LSE
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Wang 2017, Ann 
Thorac Surg (33)








Sorin pericardial showed higher 
SVD risk; P<0.001 for all other 
three valve type (lower risk- 
adjusted MTTF). No significant 
differences in SVD risk among 
the other three valve types 
(P=0.716)
Foroutan 2016,  
BMJ (34)
53,884 – Cumulative incidence 
of Death and SVD at 
10, 15 and 20 years
Xenograft [53,884] Survival 89.7%,78.4%, 57.0%, 
39.7% and 24.7% at 2, 5, 10, 
15 and 20. 10, 15, and 20 years 
freedom from SVD 94.0%, 
81.7%, 52% at (evaluated for 
7,603 pts). SVD increases rapidly 
after 10 years, and particularly 
after 15 years
Savage 2014, Ann 





11,560 2005 to 2011 Ao-H [588]; XP 
[5,396]; MP [2,144]; 
Other [293]
AVR prior 88.5% vs. reoperative 
58.7%; RR prior 7.2% vs. 
reoperative 29.9%; Prior 
operation XP increased (57% 
to 67%). MP decreased (30% 
vs. 24%) Ao-H decreased (9% 
vs. 6%) P<0.001. Reoperation 
XP increased (38% to 52%) 
MP decreased (20% vs. 17%) 
Ao-H decreased (38% vs. 28%) 
P<0.001. Ao-H most used in 
reoperation
†Reece 2014, Ann 
Thorac Surg STS 
database (36)
2,188 307# 1994 to 2010 Ross [1,094]; Non-
Ross [1,094]
Ross higher perioperative 
complications and operative 
mortality (2.7% vs. 0.9%; 
P<0.001). Ross vs. No Ross 




39,190 452 150 XP [644]; MP [376] No difference in survival (HR, 
1.04; 95% CI, 1.01–1.07). 
XP higher reoperation (HR, 
2.55; 95% CI, 2.14–3.03) and 
endocarditis (HR, 1.60; 95% 
CI, 1.31–1.94), and lower risks 
for stroke (HR, 0.87; 95% CI, 
0.82–0.93) and bleeding (HR, 
0.66; 95% CI, 0.62–0.70)
†, PM; #, all Ross operation.
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Hospital mortality ranged from 0% in patients with 
a PALSUSE score from 0 to 45.4% in patients with a 
PALSUSE score >3. Since the prognosis for IE surgery is 
highly variable, the PALSUSE score could help identify 
patients with higher hospital mortality.
Timing of surgery
The timing of surgery, especially in emergency status, is a 
lively topic of discussion in the HT and is often opposed 
to the use of medical treatment. The Heart Team works on 
the path laid out by the European Society of Cardiology (43) 
and AHA (44) who have classified the appropriate timing 
for surgery based on class and level of evidence (Figure 2, 
Table 3). The guidelines often do not correlate with real 
world scenarios faced by the multidisciplinary team. Chu 
et al. (45) highlighted that the main predictive factors 
for non-surgical referral were liver diseases [odds ratio 
(OR) for surgery: 0.16; 95% CI: 0.04 to 0.64], S aureus 
infection (OR: 0.50; 95% CI: 0.30 to 0.85) and stroke prior 
to surgical decision (OR: 0.54; 95% CI: 0.32 to 0.90). In 
contrast, patients with severe aortic regurgitation, abscess 
Figure 1 Clinical evaluation and diagnosis flowchart for LSE. For detailed explanation and references see text. ACC/AHA, American 
College of Cardiology/American Heart association; ESC, European Society of Cardiologists; IE, infective endocarditis; LSE, left side 
endocarditis; TTE, transthoracic echocardiography.
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and embolization were likely to undergo surgery. The 
authors concluded that surgical decision making in LSE 
is largely consistent with established guidelines, however 
nearly a quarter of patients with surgical indications did 
not receive surgery. Furthermore, evidence shows that the 
presence of the pathogen S. aureus in LSE was significantly 
associated with non-surgical management (45). The STS-IE 
score provides prognostic information for survival after the 
operative period, but a significant proportion of operations 
are actually never performed. 
In LSE the timing of surgical treatment is closely related 
to the appearance of the neurological complication. In 
patients with stroke, surgery should not be postponed in the 
absence of coma and cerebral hemorrhage (class IIa, level 
B). The diagnosis of minor neurological events, such as the 
appearance of a transient ischemic attack or silent cerebral 
embolism, are criteria to recommend surgery without delay 
(class 1, level B) (43).
In contrast, the manifestation of devastating neurological 
events, such as intracranial hemorrhage and brain 
localization of septic emboli with an CT features indicating 
hemorrhagic evolution, should delay surgery by at least 
1 month. According to the guidelines, repeated CT scans 
or MRI perfusion scans allow to evaluate the progression of 
Table 3 Timing for surgery based on guidelines based evidence and clinical situation
Clinical situation Surgical timing Level of evidence
Large vegetation (>15 mm), heart failure, periannular abscess Immediate intervention required Class Ia, level B
Minor cerebral event (transient ischemic attach of silent 
cerebral embolism)
Immediate intervention required Class I, level B
Stroke without evidence of cerebral hemorrhage or coma Immediate intervention possible Class IIa, level B
Stroke with suspicion of intracranial hemorrhage or cerebral 
septic emboli with potential hemorrhagic evolution
Defer surgery for 1 month; Obtain CT scan Class I, level C
Figure 2 Studies reporting the risk assessment in patients with LSE (4,8,39-42,45-50). NVE, native valve endocarditis; OMT, optimal 
medical therapy; ACC/AHA, American College of Cardiology/American Heart association; ESC, European Society of Cardiologists; IE, 
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the lesion (class IIa, level B) (43). 
Okita et al. (46) retrospectively reported a multicenter 
cohort of 568 patients undergoing surgery for active LSE. 
Of those 118 patients had non-haemorrhagic cerebral 
infarction, 54 had intracranial hemorrhage and 396 had 
no brain events. Patients with non-haemorrhagic injury 
in which surgery was postponed for 2 weeks after the 
neurologic event had a higher incidence of hospital death. 
In particular, patients who were operated between 15 and 28 
days or after 29 days from the onset of non-haemorrhagic 
cerebral infarction had higher incidences of hospital death 
compared with those who had surgery within 7 days. [Odds 
ratio 5.90 (P=0.107) and 4.92 (P=0.137)]. Conversely, 
in presence of intracranial hemorrhage, patients who 
received surgery between 8 and 21 days or after 22 days had 
lower incidences of hospital mortality compared to early 
surgery (within 7 days) [odds ratio 0.79 (P=0.843) and 0.12 
(P=0.200)].
Another decisive point of discussion is related to the 
priority between early surgery and antibiotics in the 
treatment of LSD complicated by heart failure, risk of 
embolization or in case of extensive infection. In the past 
9 years, several large studies have supported the survival 
benefit associated with the use of early surgery in patients 
with LSE in larger studies with long-term follow-up. 
Gálvez-Acebal et al. (4) in a propensity matched study 
on 417 patients with LSE with a mean follow-up was 
1.3±21 years showed that early surgery within 48 hours of 
diagnosis had a significantly better in-hospital mortality and 
late mortality rate than those managed conservatively with 
antibiotics [26.8% vs. 41.8%; absolute risk reduction (ARR), 
−15.2%; P=0.004 and 29.7% vs. 46.2%; ARR, −16.5%; 
P=0.002, respectively]. This study clearly supported the 
benefit of surgical treatment of left-sided IE especially 
in patients in which moderate or severe heart failure and 
paravalvular extension of infection occurred (4). 
In another propensity match study from Duke 
university (47), on 426 patients with LSE the mortality 
rate associated with early surgical management was 
decreased (HR, 0.27; 95% CI, 0.13–0.55). Patients who 
had an early surgical treatment were more likely to have 
Staphylococcus aureus infections, congestive heart failure, 
larger vegetations, intracardiac abscess, and undergoing 
hemodialysis without a chronic intravascular access. 
Diabetes mellitus (HR, 4.81; 95% CI, 2.41–9.62), the 
presence of chronic intravenous catheters (HR, 2.65; 95% 
CI, 1.31–5.33), and paravalvular complications (HR, 2.16; 
95% CI, 1.06–4.44) were risk factors for mortality
Mirabel et al. (48) included 198 patients who were 
prospectively evaluated for IE across 33 adult intensive 
care units (ICU) in France, and reported a 69% long-
term mortality at median follow-up time of 59.5 months in 
critical LSE. Sepsis-related Organ-Failure Assessment score 
(SOFA) calculated the day of surgery was the only factor 
independently associated with long-term mortality (HR 
=1.59; 95% CI, 0.77–3.28 for SOFA 5–9; 3.56, 1.71–7.38 
for SOFA 10–14 and 11.58, 4.02–33.35 for SOFA 15–20; 
reference category SOFA 0–4; P<0.003).
Samura et al. (49) evaluated the impact of emergency 
surgery in 152 patients (45 propensity score-matched pairs) 
with left-sided native valve IE complicated with acute 
cerebral infarction. The authors reported a significant 
higher hospital mortality in patients who underwent 
delayed surgery compared to those who received early 
valve operation (16% vs. 2%; P=0.058). The survival rates 
at 5 years in patients who were managed with early valve 
operation was higher than in delayed surgery [97% vs. 80%, 
(P=0.029)].
Wang et al. (50) compared the effect of early surgery in 
patients with prosthetic valve IE in relation to age, causative 
microorganism, intracardiac abscess, and congestive heart 
failure. Surgery group (n=145) was associated with higher 
survival rates than the antimicrobial therapy group (n=207) 
(OR for death, 0.56; 95% CI, 0.23–1.36). Predictive factors 
of in-hospital mortality were brain embolization (OR 11.12; 
95% CI, 4.16–29.73) and Staphylococcus aureus infection 
(OR 3.67; 95% CI, 1.29–9.74). 
In a study from Cleveland Clinic (5), surgery for PVE 
(n=180) was compared to NVE (n=248) in 428 consecutive 
patients who were followed for a maximum of 5 years. In-
hospital mortality was higher in PVE vs. NVE group (13% 
vs. 5.6%) and, after multivariate analysis, Staphylococcus 
aureus infection was the only independent predictors of in-
hospital death (15% vs. 8.4%; P<0.05), 6-month (23% vs. 
15%; P=0.05) and 1-year mortality (28% vs. 18%; P=0.02). 
There was a non-significant survival benefit in the PVE 
group in respect to NVE (35% vs. 29%; P=0.19).  
In large propensity matched study from the International 
Collaboration on Endocarditis–Prospective Cohort Study 
Investigators (8), including 1,025 PVE patients (aortic 
valve, 71%; mitral valve, 45.1%), there was no significant 
difference in 30-day and 1 year survival in the early valve 
replacement group compared with medical therapy (HR for 
death, 0.44; 95% CI, 0.38–0.52, P<0.001 and 0.57; 95% CI, 
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0.49–0.67, P<0.001).
Surgery for LSE
Current trends in the surgical practice
The surgery of endocarditis has been regarded as the most 
effective strategy for several categories of patients affected 
by the LSE. Long-term substitute durability is the key 
factor for the success of the surgery in patients with LSE 
(10,21,22,28,35,51-53). To date, no definitive guidelines 
support the selection of one substitute over the other, and 
the choice of the best valve remained more a matter of art 
than of science. In the last 4 decades several substitutes have 
been proposed, 5 have passed the test of time with different 
success: homograft, autograft, stented or non-stented 
xenograft prosthesis and mechanical prosthesis.  
Currently, the clinical benefits of using conventional 
biological prosthesis to replace an infected heart valve are 
well established, and this surgical option represents the 
tenet of modern valve surgery. Despite robust evidence 
suggests that the use of a biological valve, rather than 
mechanical prosthesis, is associated with further advantage 
in long-term outcomes, the effectiveness and safety of 
each substitute is related to the age and location of the 
implant (18,19,24,33,34). For mitral valve mechanical valve 
represent still an adequate choice in patients up to 70 years 
old (54), while the benefit of aortic mechanical prosthesis 
disappears after 55 years of age (38,39). The benefit in 
terms of lower risk of reoperation with mechanical valves is 
counterbalanced by the higher risk of bleeding and stroke in 
some age groups (20,54).
Evidence suggests that the choice of a homograft or an 
autograft is useful in younger high-risk patients, such as 
those with complex valve endocarditis or in patients with 
PVE. The benefit of their use becomes more evident within 
the first post-operative decade because of the reduced risk 
of recurrent infection (10,15-17,22,32,52,53). However, 
the risk of structural valve deterioration increases with 
time (10,16,22,25,27). The use of cryopreserved homograft 
does not change the extent of the survival advantage (13). 
Nevertheless, the surgical community seemed reluctant to a 
wider adoption to these substitutes for a number of reasons.
A recent analysis of the Society of Thoracic Surgeons 
(STS) database revealed that, in the United States, the 
use of stented xenograft prosthetic valves is increased and 
a total of 8,421 patients (73%) with IE cases received a 
conventional biological valves, both for primary operations 
and reoperations, compared to 3,139 patients (27%) who 
were managed with mechanical valves (35). The use of 
homograft is rare during the primary operation but is 
more common in patients requiring reoperation (32.2% 
vs. 7.0%, P<0.0001) and when extensive intervention on 
the aortic root is required (53.2%) (35). An analysis of the 
trend of the last 2 decades, based on a significant amount 
of observational data, has showed that the use of homograft 
has decreased over time in cases of first-time replacement of 
the aortic valve (from 9.4% to 5.6%) and for reoperations 
(from 37.5% to 28.5%) (35). 
The reasons for the low use of mechanical valves and 
homografts are complex and multifactorial. More than two 
decades ago data reported by Washington University of 
St Louis showed that 50% of patients with IE underwent 
surgery with mechanical prosthesis while since 2009 only 
14% of the patients were treated with this type of valve. The 
evident change in the surgeons’ attitude has been probably 
determined on the one hand by the reported trends towards 
better survival and complication rate with biological valves, 
and on the other, by the increase in re-hospitalization for 
clinical events related to anticoagulation-related problems 
in recipients of mechanical valves (20,54). In this scenario, 
managing both the short term and the long-term adverse 
event, including the prevention of thrombotic complication, 
can be the drivers of the surgical decision-making process 
because of the potential economical implications for the 
institutions. In fact, the costs of managing valve thrombosis 
was estimated to exceed $30,000 for a single event. The 
costs of acute management of embolism and anticoagulant-
related hemorrhage were between $8,000 and $11,500 (55).
The use of homograft and allograft for LSE—when and 
how
The reluctance shown by surgeons for the widespread 
adoption of cryopreserved homograft in IE finds its roots 
in lack of RCT investigating the effective benefit of the 
use of these substitutes (10,13,16,22,31,32,51,56,57). 
Evidence from several reports have reported no significant 
differences in overall mortality and infection recurrence 
when comparing mechanical versus biological substitutes 
(13,31,51,56,57). Klieverik et al. (56) revealed a similar 
rate of recurrent endocarditis in patients who underwent 
homografts or mechanical prosthesis implantation, but a 
lower freedom from reoperation (76% vs. 93% respectively). 
Sabik et al. (32) showed that patients with prosthetic IE, 
including 78% with periannular and radical abscesses, had 
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a freedom from recurrent infection of more than 2 years 
of 95% and an operating mortality of 3.9% when treated 
with a homograft. Although the risk of homograft root 
re-operation for structural valve deterioration is higher, 
reduced rate of reinfection was noted in the long-term 
follow-up (between 14 and 27 years) (10,16,17,22,25,27,53), 
p r o b a b l y  d u e  t o  t h e i r  f a v o r a b l e  r e s p o n s e s  t o 
antibiotics (16,22). 
Despite the survival benefits associated with the use of 
pulmonary autograft (PA) are well established (29,57-62), 
its use to replace the aortic valve is recommended only in 
the US guidelines (Class II b, Evidence Level C) (63) and 
not mentioned in the European guidelines (43). The use of 
autograft in the setting of the LSE has been considerably 
reduced because of the indisputable technical complexity 
in the execution of the Ross operation. The data from STS 
database have showed 3-fold increase in operative mortality 
with Ross operation compared with conventional AVR, 
probably as an effect of lack of experience of low volume of 
cases (36,64). Despite these evident criticalities, the use of 
PA in patients with LSE is indicated at a young age or with 
contraindication for long-term anticoagulant treatment, 
in women of childbearing age, in PVE and in patients who 
choose this substitute for the type of style of life they lead 
(12,65-68). However, it should be taken into consideration 
that potential complications of this operation involve both 
the aortic and pulmonary valve and carry an additional 
clinical burden (69). 
Surgery in complex LSE
Kim et al. (13) reported outcomes of 131 patients treated 
with extensive and radical surgery for LSE. Homografts 
but also mechanical valves or xenografts have been used in 
these cases. The authors found that abscess formation had 
an incidence of 43.09%, which is higher than the mean 
frequency (36–38%) for LSE of native valve (10,21) and PV 
(58%) reported by several international studies (3). Abscess 
formation was treated in 40.5% with a mechanical valve and 
in 29.5% with xenograft.
The selection of the type of graft to be used should be 
guided by several parameters including age, extension of 
the infection (especially to the mitral valve), involvement 
of other heart structures and resistance to infections. The 
latter is particularly important since redo surgery in case 
of reinfection is particularly demanding and burdened by 
increased perioperative risk and poor early and mid-term 
outcomes. It is noteworthy that reinfection of synthetic 
prostheses or prosthetic materials after complex endocarditis 
were reported as more daunting and technically demanding 
than reinfection occurring on a previous homograft 
(10,52,53,62,66-69) (Figure 3).
In this context, evidences on safety and durability of 
homograft has been widely reported. A pivotal study of 
Stanford University (31) revealed a reinfection rate of 
2% at 10 years with the majority of the cases occurring 
following aortic valve endocarditis surgery within the 
first year. More recently, the group from Cleveland 
clinic confirmed the long-term durability and safety of 
homografts for LSE with the additional benefit of improved 
postoperative hemodynamics and ventricular remodeling. 
The fact that no difference in outcomes was demonstrated 
between mechanical and biological prostheses suggests 
that in complex endocarditis and in patients with extensive 
PVE, the choice of the use of an allogeneic tissue is a 
priority (5,21).
There is currently a sizable body of evidence to support 
the use of homografts in the setting of complex LSE. A 
report (17) showed a low recurrence of endocarditis in 
homograft even in complex cases. The larger series by 
Erasmus group (16) showed very solid results in terms 
of mortality and durability. The authors published their 
follow-up at 27 years underlying the importance of 
homografts in complex endocarditis. Musci et al. (28) used a 
homograft aortic roots in active IE with periannular abscess 
formation in a large series of patients with LSE showing 
satisfactory early and long-term results. Finally, as reported 
by Perrotta (15) survival benefit with the use of a homograft 
is higher than in prosthetic valves (5-year cumulative 
survival 88% versus 66% in prostheses).
Although structural valve deterioration is considered 
the Achilles’ heel responsible for the limited use of 
allogenic tissue (10,25,27,68,69), relapse of infection 
represents a daunting problem in patients treated for 
complex active LSE and should be given consideration. 
Notably, the reoperation for a relapsing infection carries a 
higher mortality than the reoperation for structural valve 
deterioration or dysfunction of an aortic homograft inserted 
in aortic root position (4–10%) (10,69,70). 
Another important point is the reinfection in presence 
of the synthetic material. The strong inflammatory reaction 
elicited by the foreign material constituting the stent 
of mechanical or biological prosthetic valves demands 
for extensive demolition and debridement increasing 
the complexity of the procedure. However, reoperation 
after previous homograft is considered less demanding 
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even in the presence of massive calcification of the aortic 
root (71-73).
In LSE abscess formation is common. Avoiding the use 
of a homograft in favor of a prosthetic valve in aortic IE 
implies to treat the abscess with a circumferential patch to 
repair the ventricular-aortic discontinuity. Similarly, in the 
case of localized lesions involving only a part of the aortic 
annulus, the aorto-mitral continuity or aortic root, the 
cardiac structure still needs to be reconstituted with use of a 
partial Dacron or equine pericardial patch (3,5,21,26,30,32). 
Recurrence of LSE involving the myocardium underlying 
the left coronary cusp is at even higher-risk and may require 
a Bentall or Cabrol operation.
Infection of more than one valve has been reported 
in 24.2% to 46.8% of the cases (3,10,13,52) with mitral 
or tricuspid valve being more commonly involved in 
intravenous drugs user (11).
Clearly, complex LSE treated with prosthetic valves 
could lead to a further increase in the risk of mortality in 
the event of extensive reinfection of two prostheses (3,26). 
In a very recent Harvard series, associated mitral valve 
involvement reached up 25% of the cases (13). We have 
proposed the use of a double homograft in complex LSE 
with extension to aorto-mitral junction and mitral including 
both total and partial mitral insertion techniques with 
satisfactory results at 18 years (10,52,53,69).
Surgery and ethical implication
As recommended by current guidelines, selection of the 
most appropriate valve replacement strategy in LSE 
should consider the longevity of the biological substitutes, 
the potential recurrence of infection and the risk of redo 
surgery. The best choices are made through a shared 
decision-making process that includes the patient, the 
patient’s family, an interventional cardiologist, a cardiac 
surgeon and, preferably, the patient’s general cardiologist or 




Figure 3 Aortic abscess (A,C) treated using a prosthetic valved conduit with mechanical valve (B,D).
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Patient’s preferences and will also take a considerable 
part in the decision-making. Patients may be discouraged 
from large and demanding operation. Therefore, the role 
of the heart team is fundamental in providing detailed 
explanations of the indications, the steps of the procedure, 
the potential complications and the postoperative course 
to allow an informed decision-making. In educating the 
patient, the experts should explain the potential need for 
extensive debridement to obtain good and stable results. For 
example, proposing a faster operation by recommending a 
prosthetic valve instead of the use of autologous or allogenic 
tissue in the context of significant involvement of the aortic 
or mitral valves, can provide misleading information about 
a situation with a high potential for recurrence of infection. 
The decision on the surgical option and the choice of the 
ideal substitute always derives from a balance between the 
risk of the operation that the surgeon should perform and 
the obtainable benefit. In the case of complex LSE, both 
the risk of the procedure and the potentially even higher 
risk of a redo operation for infection relapse or valve 
degeneration should be taken into account. Obviously, these 
considerations are also ultimately subjected to the surgeon 
and unit’s experience in complex procedures and the option 
of referral to tertiary centers should be explored according 
to the clinical conditions.
Interestingly, Stulak et al. (64) addressed the ethical 
problem after the use of autograft in Ross’s operation. 
The use of biological derivatives in fact poses some 
ethical problems when the chances of procedure failure or 
reintervention are not negligible. The problem of durability 
of allogeneic and autologous tissues should be addressed 
with the patient during the counselling process. On the 
other hand, the benefit of low risk of infection relapse and 
the impact on quality of life related to the avoidance of life-
long anticoagulant therapy should be discussed.
Take-home messages and an algorithm based 
on evidence 
The evidence discussed above indicates that modern LSE 
surgery should involve the use of a different strategies 
according to the location and extent of the infection. 
Conventional stented xenograft and mechanical prosthetic 
should be considered similar alternatives for localized LSE 
or combined with patch reconstruction in case of more 
abscess formation; mechanical valves should be preferred 
in cases of mitral valve endocarditis and biological valves 
should be used in patients older than 55 years of age in 
aortic position. 
Due to its higher risk of structural valve deterioration, 
lack of availability and difficult learning curve, the 
use of homografts is limited to PVE or when complex 
reconstruction of the mitro-aortic curtain or aortic root 
is needed. The miniroot implant is probably the most 
adaptable technique for complicated LSE and most 
appropriate in case of demolitive surgery. Cryopreserved 
mitro-aortic tissue allows the complete or partial 
replacement of the mitral valve in case of aggressive lesions 
involving the trigones, the aortic root or cardiac and 
extracardiac fistulas. However, this type of surgical approach 
requires adequate surgeon’s and center’s experience.
The use of the autograft can be considered in young 
patients or in particular conditions such as women in 
childbearing age or in case of contraindications to long-
term anticoagulation. The use of PA should be limited to 
centers that have proven experience with solid results and 
only to cases where a conventional biological or mechanical 
prosthesis is not indicated for clinical or technical reasons.
On the basis of the evidence examined in this study, 
we propose an algorithm assisting the choice of the valve 
substitute in different clinical conditions (Figures 4,5). In this 
algorithm, technical, anatomical and imaging determinants 
are considered, as well as the clinical characteristics of the 
patient, the orientation of the guidelines and institutions 
with the greatest experience in the treatment of LSE. 
Due to the strong impact on post-operative mortality, 
special relevance should be given to timing, which influences 
the risk of neurological complications, and the extension of 
the infection. Despite evidence suggests that early surgery 
may improve survival in patients with complicated IE, an 
increased risk of recurrence and postoperative valvular 
dysfunctions has been reported (6,11,14,23,26,30). 
The most important factors associated with long-term 
outcomes are preoperative multiorgan failure, prosthetic 
mechanical valve IE, vegetation size ≥15 mm, and timing of 
surgical treatment. Importantly, up to one third of potential 
candidates do not undergo surgery and these patients 
experience extremely high mortality rates (37,74,75).
The lack of RCT in this field and the difficulty to design 
this type of studies in the case of non-elective conditions 
further complicates the possibility to achieve a univocal 
consensus on the best strategy to be adopted in each form 
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Figure 4 Take-Home Messages and Clinical Algorithm for the Management of Left Side Endocarditis. GMT, guide medical therapy; ACC/
AHA, American College of Cardiology/American Heart association; ESC, European Society of Cardiologists; IE, infective endocarditis; 
LSE, left side endocarditis; TTE, transthoracic echocardiography.
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